30 March 2009
Angiotensin receptors in hormone-independent prostate cancer cell line DU145: Presence of two variants of angiotensin type 1 receptor
Małgorzata SidorkiewiczA, Elżbieta Rebas, Marta Szymajda, Hanna Lawnicka, Marek Pawlikowski, Agnieszka LachowiczMed Sci Monit 2009; 15(4): BR106-110 :: ID: 869609
Abstract
Background: Recently, the involvement of the renin-angiotensin system in the proliferation of prostate cancer has been suggested. There is increasing evidence that angiotensin II receptor type 1 (AT1) is expressed in a variety of cancer cells and tissues and may have a role in tumor growth, angiogenesis, and invasive activity of malignant lesions in vivo. The implications of data referring to an angiotensin receptor in hormone-independent human prostate cancer DU145 cells are unclear. Angiotensin II has been shown to inhibit the proliferation of DU145 cell lines. However, it is known that AT1 stimulates cell proliferation and that angiotensin II receptor type 2 (AT2) induces apoptosis and inhibits cell proliferation.
Material/Methods: The aim of our study was to investigate, by means of immunohistochemical and reverse transcriptase polymerase chain reaction assays, the type of angiotensin II receptor that is present in DU145 cells.
Results: In DU145-derived complementary deoxyribonucleic acid (cDNA), a polymerase chain reaction assay revealed 2 AT1-specific PCR products (93 bp and 126 bp). DU145-derived cDNA did not reveal AT2 expression at a level sufficient for detection by PCR. In cultured cells, immunohistochemical testing revealed a positive reaction in cultures immunostained with anti-AT1 antibody but not in those immunostained with AT2 antibody.
Conclusions: The inhibitory effect of angiotensin II on the proliferation of DU145 cells is exerted via AT1. It is possible that presence of 2 variants of AT1 in that cancer cell line is essential to produce the biological effects of angiotensin
Keywords: DU-145, human prostate cancer, Base Sequence, DNA Primers, DNA, Complementary, Prostatic Neoplasms - pathology, Receptor, Angiotensin, Type 1 - metabolism, Reverse Transcriptase Polymerase Chain Reaction
Editorial
01 May 2024 : Editorial
Editorial: First Regulatory Approval for Adoptive Cell Therapy with Autologous Tumor-Infiltrating Lymphocytes (TILs) – Lifileucel (Amtagvi)DOI: 10.12659/MSM.944927
Med Sci Monit 2024; 30:e944927
In Press
12 Mar 2024 : Clinical Research
Tissue Inhibitors of Metalloproteinase 1 (TIMP-1) and 3 (TIMP-3) as New Markers of Acute Kidney Injury Afte...Med Sci Monit In Press; DOI: 10.12659/MSM.943500
12 Mar 2024 : Review article
Optimizing Behçet Uveitis Management: A Review of Personalized Immunosuppressive StrategiesMed Sci Monit In Press; DOI: 10.12659/MSM.943240
12 Mar 2024 : Clinical Research
Metabolomic Alterations in Methotrexate Treatment of Moderate-to-Severe PsoriasisMed Sci Monit In Press; DOI: 10.12659/MSM.943360
14 Mar 2024 : Clinical Research
Renal Dysfunction Increases Risk of Adverse Cardiovascular Events in 5-Year Follow-Up Study of Intermediate...Med Sci Monit In Press; DOI: 10.12659/MSM.943956
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952